Skip to main content
. 2017 Aug 21;8(42):73050–73062. doi: 10.18632/oncotarget.20377

Figure 4. Comparison of efficacy across drugs.

Figure 4

OR with 95% CI of network meta-analysis for CR (A), PR (B), TR (C) and ASE (D).